Synonyms: SU-6668 | TSU-68
Compound class:
Synthetic organic
Comment: Orantinib is a multi-kinase inhibitor.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
The only Phase 3 study designed to evaluate orantinib's efficacy (NCT01465464) was terminated. |
Mechanism Of Action and Pharmacodynamic Effects |
Orantinib inhibits several receptor tyrosine kinases including PDGFRβ, VEGFR2, and FGFR1 [2], but does not inhibit EGFR [1]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01465464 | Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma | Phase 3 Interventional | Taiho Pharmaceutical Co., Ltd. |